Accord’s Teriparatide And Fresenius Kabi’s Pegfilgrastim Satisfy CHMP
Two Biosimilars And Three Generics Endorsed As Ipique Sponsor Demands Review
Executive Summary
Positive CHMP opinions recommending European marketing authorizations have been granted for Accord’s teriparatide and Fresenius Kabi’s pegfilgrastim biosimilars, while the sponsor for an ophthalmic version of bevacizumab has asked the EMA to take a second look at the rejection of its application. Three Accord generics were also endorsed by the CHMP at its January meeting.